Most depression patients don't remit on first antidepressant

Most depression patients don't remit on first antidepressant

UNITED STATES – November 15, 2026 -- Suicide killed 48,824 Americans in 2024, according to the CDC. By our calculation, that is about 16% more than the roughly 42,000 American women who die of breast cancer each year, per the American Cancer Society.

Dr. David Mahjoubi, founder of NutraBrain Clinic in the US, uses that comparison in an essay arguing that standard depression treatment is too slow. He says the default sequence of antidepressants has barely changed since fluoxetine was approved in 1987.

A 2023 reanalysis found about one in four patients remit on their first antidepressant

The essay leans on STAR*D, an NIH-funded trial of more than 4,000 patients. The original analysis reported remission in about 37% of patients on the first drug. A 2023 reanalysis in BMJ Open, using the original protocol's criteria, put it at 25.5%. That works out to roughly 75% of patients not reaching remission on the first medication.

Odds fell with each later step, to about 10% by the fourth attempt. The essay says each failed trial costs four to eight weeks, and estimates that one-third of treated patients go on to treatment-resistant depression.

Depression raises the risk of death from any cause 1.8 times, studies cited in the essay find

A meta-analysis of 25 studies covering more than 106,000 people found that risk, with most of the excess deaths from natural causes such as cardiovascular disease. A Danish cohort of 126,573 diagnosed people, published in European Neuropsychopharmacology in 2024, found life expectancy cut by about 14 years in men and 10 years in women. A 2025 World Psychiatry meta-analysis also found higher mortality, while noting that some of the excess risk reflects co-occurring health problems.

Esketamine gained FDA approval in 2019, while racemic ketamine stays off-label

The essay cites a 2006 NIMH trial in which a single ketamine infusion produced antidepressant effects within hours in treatment-resistant patients. The FDA approved esketamine nasal spray for treatment-resistant depression in 2019.

Racemic ketamine is prescribed off-label for depression. The author says its effects need ongoing treatment to last, and it is not appropriate for people with a history of psychosis or current illicit drug use. He recommends seeing a psychiatrist first and staying under psychiatric care during therapy.

NutraBrain Clinic sells physician-led, at-home ketamine therapy. The essay does not give a price.

Anyone in crisis can call or text 988, the Suicide & Crisis Lifeline.

Published by:
newsonline24_team
Markets